Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Expands By 2,750.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 11,400 shares, a growth of 2,750.0% from the March 31st total of 400 shares. Based on an average daily trading volume, of 206,900 shares, the days-to-cover ratio is presently 0.1 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC stock traded up $0.00 on Friday, reaching $0.04. 22,308 shares of the company’s stock were exchanged, compared to its average volume of 70,737. Oncotelic Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.05. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.02 and a quick ratio of 0.02. The company’s fifty day simple moving average is $0.04 and its 200 day simple moving average is $0.04.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.